|
Panel Gives Nod to Novo’s Long-Acting Insulin Despite Heart Concerns
FDA advisers voted 8–4 Thursday in support of approval for Novo Nordisk’s ultra-long acting insulin candidates Tresiba and Ryzodeg for Type 1 and Type 2 diabetes despite lingering worries about cardiovascular effects.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives